Shares of TDIC are collapsing approximately 77.00% on Thursday, May 14, 2026, falling from a Wednesday, May 13 close of $23.05 to approximately $5.30 — a violent post-parabolic reversal that is unwinding Wednesday's extraordinary 876.69% single-session surge

LWLG shares are down approximately 15% in Thursday's trading session following Q1 2026 earnings released after the close on May 13 — a classic "buy the rumor, sell the news" reaction. Primary catalyst: Despite beating modest top-line expectations with $29,000 in revenue, net losses widened to $6.3 million and management highlighted persistent foundry capacity constraints that are delaying customer advancement to the manufacturing stage.

ALMU shares are down approximately 16% in premarket trading on May 14, 2026, following the release of fiscal Q3 2026 financial results after the close on May 13. Primary catalyst: Aeluma narrowed and effectively cut its full-year FY2026 revenue guidance to $4.2M–$4.6M, trimming the upper end of the prior $4.0M–$6.0M range by $1.4 million, citing government shutdown-related contract delays.

RGNX shares are down approximately 22% in premarket trading on May 14, 2026, despite the company announcing positive topline results from the pivotal Phase III AFFINITY DUCHENNE® trial of RGX-202 for Duchenne muscular dystrophy. Primary catalyst: Q1 2026 revenue collapsed to $6.4 million from $89.0 million in Q1 2025 — a 93% year-over-year decline — driven by the expiration of ZOLGENSMA® patent royalties and the absence of the $70 million Nippon Shinyaku milestone recognized in Q1 2025.

ENVX shares are down approximately 13% in premarket trading on May 14, 2026, following the company's Q1 2026 earnings release after the close on May 13. Primary catalyst: Despite beating both revenue and EPS estimates, Enovix's CEO acknowledged that smartphone battery qualification timelines are taking longer than expected, disappointing investors who were anticipating a clearer and nearer-term path to commercial smartphone revenue.

MDXH shares are plummeting approximately 41% in premarket trading on May 14, 2026, following a Q1 2026 earnings release after the May 13 close that contained several significant negative disclosures. Primary catalyst: MDxHealth announced it is discontinuing its Resolve UTI business due to an uncertain reimbursement environment, eliminating a meaningful revenue stream and triggering a full strategic pivot.

PDFS shares are down approximately 12% in premarket trading on May 14, 2026, following the announcement of a dilutive equity offering priced at a steep discount to the prior close. Primary catalyst: PDF Solutions priced an upsized public offering of 4,568,308 shares at $44.00 per share — roughly 14% below the May 13 closing price of $50.95.

DOCS shares are down approximately 23% in premarket trading on May 14, 2026, following a post-earnings selloff that began after the close on May 13. Primary catalyst: Doximity issued fiscal year 2027 annual revenue guidance of $664M–$676M, falling well short of the Wall Street consensus near $697.4 million.

Analysts expect Q1 fiscal 2026 adjusted EPS of $0.29, aligning with company guidance of $0.24-$0.30. Consensus revenue forecast is $1.36 billion, down about 4.5% from $1.424 billion in Q1 last year, matching guided 4%-6% decline.

Analysts expect Q1 2026 revenue of approximately $205 million, more than tripling from $62.5 million in Q1 2025. Consensus EPS estimate is -$0.06, an improvement from -$0.11 per share a year ago.

Analysts expect Q1 2026 revenue of approximately $39.4 million, aligning with company guidance of $38-40 million and implying over 800% year-over-year growth. Consensus EPS estimate is a loss of -$0.03 to -$0.06 per share, reflecting heavy investments in growth amid rapid expansion.

Analysts expect Q1 2026 revenue of approximately $944 million, up about 34% from $701 million in Q1 2025. Consensus EPS estimate is -$0.13, an improvement from prior quarters amid ongoing investments in banking services.

Analysts expect Q1 2026 revenue of approximately $930 million, aligning closely with company's guidance of $925–$950 million. Consensus EPS estimate stands at $0.17, with focus on path to profitability after Q4 2025 net loss of $0.55 per share.

Analysts expect Q1 2026 revenue of $316 million, aligning with company's guidance of $315-317 million and implying 38% year-over-year growth. Consensus EPS (earnings per share) estimate stands at $0.06, reflecting continued profitability improvements on a non-GAAP basis.

Analysts expect Q1 2026 revenue of approximately $227 million, aligning closely with company's guidance midpoint of $227 million. Consensus non-GAAP EPS estimate stands at $2.20, within Nova's guided range of $2.13 to $2.25.

Analysts expect Q1 2026 EPS of 0.91 CNY (~$0.13 USD), down 23% year-over-year from 1.19 CNY in Q1 2025. Consensus revenue forecast stands at 18.55 billion CNY (~$2.57 billion USD), reflecting a projected 20% decline from Q1 2025's 23.3 billion CNY.

Analysts expect Q1 2026 EPS of $6.92 and revenue of $1.55 billion, reflecting continued momentum from 2025's record performance. Credicorp follows a calendar fiscal year, with Q1 spanning January to March 2026.

Analysts expect Honda Motor (HMC) to report Q4 revenue around $33 billion for the fiscal year ended March 31, 2026 (FYE March 31, 2026). Consensus EPS forecast stands at approximately -$5.74 per ADR share, reflecting anticipated heavy losses from EV strategy reassessment.

Analysts expect Q1 2026 revenue of $1.01 billion, up 12.6% from $897.1 million in Q1 2025. Consensus EPS estimate is -$0.11, an improvement from -$0.24 reported last year.

Resideo Technologies (REZI) shares plunged 15.91% to close at $30.85, following a previous close of $36.68. The primary catalyst was disappointing Q2 guidance, with revenue projected at $1.916-$1.94 billion (below consensus $1.978 billion) and adjusted EPS at $0.71-$0.75 (below $0.84).